secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0000950170-22-024988
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium Q3 net loss $13.7M ($0.40/shr); Metacrine deal to add $35M cash
-------------------------------------------------------------------------

- Net loss $13.7M ($0.40/shr) vs $10.3M ($0.35) in Q3 2021; R&D $8.8M, G&A $4.5M.
- Cash, equivalents and investments $44.5M as of Sep 30; pending Metacrine acquisition expected to add ~$35M cash, extending runway into 2024.
- Positive interim itolizumab data in lupus nephritis: 83% achieved complete or partial response by week 28; 67% had >80% UPCR reduction.
- Initiated Phase 2 study of EQ101 in alopecia areata (30 subjects) and Phase 1 study of EQ102 in celiac disease; data expected in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000095017022024988/0000950170-22-024988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000095017022024988/eq-20221114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer